Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001332349 | SCV001524645 | uncertain significance | Combined oxidative phosphorylation defect type 8 | 2019-09-18 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Ambry Genetics | RCV002546552 | SCV003681153 | uncertain significance | Inborn genetic diseases | 2022-06-24 | criteria provided, single submitter | clinical testing | The c.1157C>T (p.A386V) alteration is located in exon 8 (coding exon 8) of the AARS2 gene. This alteration results from a C to T substitution at nucleotide position 1157, causing the alanine (A) at amino acid position 386 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV003127809 | SCV003803176 | uncertain significance | not provided | 2024-11-22 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Baylor Genetics | RCV003147618 | SCV003836177 | uncertain significance | Leukoencephalopathy, progressive, with ovarian failure | 2022-01-27 | criteria provided, single submitter | clinical testing |